39 results
F-3
KMDA
Kamada Ltd
11 Sep 23
Shelf registration (foreign)
7:01am
in comparison to the pre-COVID-19 pandemic sales and we anticipate this trend to continue during 2023 and beyond.
We believe that sales of CYTGOM … or blood bank setting, as an immediate response to a variety of unmet medical needs, including pandemic outbreaks, as well as possible treatment
6-K
EX-99.1
KMDA
Kamada Ltd
22 Nov 22
Kamada Reports Strong Third Quarter Financial Results Demonstrating Successful Strategic Transition and Reiterates 2022 Financial Guidance
7:00am
of the COVID-19 pandemic, its scope, effect and duration, availability of sufficient raw materials required to maintain manufacturing plans, disruption … to the supply chain due to COVID-19 pandemic, continuation of inbound and outbound international delivery routes, continued demand for Kamada’s products
6-K
EX-99.1
KMDA
Kamada Ltd
7 Nov 22
Kamada Provides Update on Recent Progress Achieved in Ongoing Pivotal Phase 3 Clinical Trial of Inhaled AAT
7:00am
Antitrypsin Deficiency (AATD).
Earlier this year, following the moderation of the COVID-19 pandemic, the study was expanded to additional sites across … to, the continued evolvement of the COVID-19 pandemic, its scope, effect and duration, unexpected results of the Phase 3 clinical study, delays
6-K
EX-99.1
KMDA
Kamada Ltd
19 Oct 22
Kamada Awarded $22 Million Extension of Canadian Supply Tender
7:00am
-looking statements as a result of several factors including, but not limited to, the continued evolvement of the COVID-19 pandemic, its scope, effect … and duration, disruption to the supply chain due to COVID-19 pandemic, Kamada’s ability to successfully integrate the new product portfolio into its
6-K
EX-99.1
cndj8jf
17 Aug 22
Report of Foreign Private Issuer
7:00am
6-K
EX-99.1
rez72iqba9lxt5m2
6 Jul 22
Kamada Announces $11.4 Million International VARIZIG® Procurement Agreement
6:01am
6-K
EX-99.1
uato9ocmjin
17 May 22
Reiterates Revenue and Profitability Guidance with Significant Growth Expected in 2022
7:05am
6-K
EX-99.1
khl6d3q
17 May 22
Report of Foreign Private Issuer
7:00am
6-K
EX-99.1
4evpy 20u2
15 Mar 22
Kamada Issues 2022 CEO Letter to Shareholders
7:11am
6-K
EX-99.1
6hp8np80ov7sp c0
15 Mar 22
Provides Revenue and Profitability Guidance with Significant Growth Expected in 2022
7:02am
6-K
EX-99.1
bojgnk8pcc efw
14 Mar 22
Kamada Expands U.S. Leadership Team with Two Key Appointments
7:01am
6-K
EX-99.1
s6qpruw i6
22 Nov 21
Report of Foreign Private Issuer
7:06am
6-K
EX-99.1
lcorytxpjmctlje33m
22 Nov 21
Report of Foreign Private Issuer
7:02am
6-K
EX-99.2
kqab 0ecz
22 Nov 21
Report of Foreign Private Issuer
7:02am
6-K
EX-99.1
aup7cl5av5hwzrw42ta7
11 Aug 21
Kamada Reports Second Quarter and First Half 2021 Financial Results, Recent Achievements and Corporate Development Activities
7:02am
6-K
EX-99.2
7a99nk3wtqyls0lcrpl
11 Aug 21
Kamada Reports Second Quarter and First Half 2021 Financial Results, Recent Achievements and Corporate Development Activities
7:02am
6-K
EX-99.1
wiaxq3qs
12 May 21
Kamada Reports First Quarter 2021 Financial Results, Recent Achievements and Corporate Development Activities
7:06am
6-K
EX-99.2
9aabt70
12 May 21
Kamada Reports First Quarter 2021 Financial Results, Recent Achievements and Corporate Development Activities
7:06am